As wild-type p53 is difficult to detect by immunohistochemistry (IHC) on tissue sections with currently available antibodies, we took advantage of oncogenic Kras-driven lung and pancreatic cancer models harbouring a p53R172H mutant allele (LSL-KrasG12D; LSL-p53R172H), which demonstrate similar histologic progression to the MADM models11, 20. Here, TP53 is linked to pancreatic neoplasm.